Overcoming upstream and downstream process barriers for large-scale AAV production

Given the broad treatment potential and demonstrated efficacy of recently approved viral vector-based gene therapies, there is an established need for reproducible and consistent manufacturing solutions that yield high titer, high quality viral particles for clinical applications.

Download now to learn about key barriers to addressing clinical needs and market supply of gene therapies, and how the industry is evolving to implement solutions to overcome these issues.

You’ll learn about the following:

• An end-to-end solution for commercial production of AAV
• How new products and technologies can help address production efficiency, regulatory concerns, and scale‑up of AAV
• How critical manufacturing challenges are currently being addressed by gene therapy developers